BioSante Pharmaceuticals News
Most Popular BioSante Pharmaceuticals Story
BioSante axes 25% of workforce after big miss in female libido gel trials
BioSante Pharmaceuticals ($BPAX) alerted investors this morning to its plan to move forward after the colossal failure of its late-stage trials for its female libido gel last month. To save cash, the Read more...
Latest Headlines
- December 15, 2011
- July 21, 2011
- February 14, 2011
- March 11, 2010
- February 22, 2010
- August 13, 2009
- June 30, 2009
- September 8, 2008
- June 23, 2008
- June 10, 2008
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
